RINVOQ

This brand name is authorized in Austria, Australia, Brazil, Canada, Ecuador, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Turkey, United Kingdom, United States, South Africa

Active ingredients

The drug RINVOQ contains one active pharmaceutical ingredient (API):

1 Upadacitinib UNII NEW4DV02U5 - UPADACITINIB HEMIHYDRATE

Upadacitinib is a selective and reversible Janus kinase (JAK) inhibitor. In human cellular assays, upadacitinib preferentially inhibits signalling by JAK1 or JAK1/3 with functional selectivity over cytokine receptors that signal via pairs of JAK2. JAK1 is important in inflammatory cytokine signals while JAK2 is important for red blood cell maturation and JAK3 signals play a role in immune surveillance and lymphocyte function. Read about Upadacitinib

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
RINVOQ Prolonged-release tablet	European Medicines Agency (EU)	MPI, EU: SmPC
RINVOQ Extended-release tablet	FDA, National Drug Code (US)	MPI, US: SPL/PLR

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L04AF03		L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AF Janus-associated kinase (JAK) inhibitors
Discover more medicines within L04AF03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 11979L, 11989B
Country: BR	Câmara de Regulação do Mercado de Medicamentos	Identifier(s): 543720060004207, 543720060004307
Country: CA	Health Products and Food Branch	Identifier(s): 02495155
Country: EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	Identifier(s): 5591-MEE-1020, 7080-MEE-0322
Country: EE	Ravimiamet	Identifier(s): 1808951, 1808962, 1808973, 1809312, 1809323, 1860588, 1860601, 1860612, 1860623, 1887857, 1887891
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 1191404001
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 091893
Country: FR	Base de données publique des médicaments	Identifier(s): 65852428
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 380675
Country: HK	Department of Health Drug Office	Identifier(s): 66872
Country: IE	Health Products Regulatory Authority	Identifier(s): 89057, 89155
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 8740, 9072, 9307
Country: IT	Agenzia del Farmaco	Identifier(s): 048399012, 048399024, 048399036, 048399048, 048399051, 048399063, 048399075, 048399087, 048399099, 048399101, 048399113
Country: JP	医薬品医療機器総合機構	Identifier(s): 3999048G1028, 3999048G2024, 3999048G3020, 3999048G4027
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1089080, 1089081, 1089082, 1089083, 1089084, 1093301, 1093302, 1093303, 1093304
Country: NL	Z-Index G-Standaard, PRK	Identifier(s): 201073
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 20573, 22034
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100427770
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W66589001, W68028001, W69486001, W69486002
Country: TR	İlaç ve Tıbbi Cihaz Kurumu	Identifier(s): 8680656080575, 8680656080582
Country: US	FDA, National Drug Code	Identifier(s): 0074-2306
Country: ZA	Health Products Regulatory Authority	Identifier(s): 54/3.1/0187